Portal de Periódicos da CAPES

The potential role of glucagon-like peptide-1 or its analogues in enhancing glycaemic control in critically ill adult patients

2010; Wiley; Volume: 13; Issue: 2 Linguagem: Inglês

10.1111/j.1463-1326.2010.01311.x

1463-1326

J. Combes, Sophie Borot, F. Mougel, A. Penfornis,

Diabetes Treatment and Management

Diabetes, Obesity and MetabolismVolume 13, Issue 2 p. 118-129 The potential role of glucagon-like peptide-1 or its analogues in enhancing glycaemic control in critically ill adult patients J. Combes, J. Combes Department of Endocrinology-Metabolism and Diabetology-Nutrition, Jean Minjoz Hospital, University of Franche-Comté, Boulevard Fleming, Besançon, FranceSearch for more papers by this authorS. Borot, S. Borot Department of Endocrinology-Metabolism and Diabetology-Nutrition, Jean Minjoz Hospital, University of Franche-Comté, Boulevard Fleming, Besançon, FranceSearch for more papers by this authorF. Mougel, F. Mougel Department of Endocrinology-Metabolism and Diabetology-Nutrition, Jean Minjoz Hospital, University of Franche-Comté, Boulevard Fleming, Besançon, FranceSearch for more papers by this authorA. Penfornis, Corresponding Author A. Penfornis Department of Endocrinology-Metabolism and Diabetology-Nutrition, Jean Minjoz Hospital, University of Franche-Comté, Boulevard Fleming, Besançon, FranceAlfred Penfornis, Department of Endocrinology-Metabolism and Diabetology-Nutrition, Jean Minjoz Hospital, EA 3920, University of Franche-Comté, Boulevard Fleming, Besançon 25000, France.E-mail: alfred.penfornis@univ-fcomte.frSearch for more papers by this author J. Combes, J. Combes Department of Endocrinology-Metabolism and Diabetology-Nutrition, Jean Minjoz Hospital, University of Franche-Comté, Boulevard Fleming, Besançon, FranceSearch for more papers by this authorS. Borot, S. Borot Department of Endocrinology-Metabolism and Diabetology-Nutrition, Jean Minjoz Hospital, University of Franche-Comté, Boulevard Fleming, Besançon, FranceSearch for more papers by this authorF. Mougel, F. Mougel Department of Endocrinology-Metabolism and Diabetology-Nutrition, Jean Minjoz Hospital, University of Franche-Comté, Boulevard Fleming, Besançon, FranceSearch for more papers by this authorA. Penfornis, Corresponding Author A. Penfornis Department of Endocrinology-Metabolism and Diabetology-Nutrition, Jean Minjoz Hospital, University of Franche-Comté, Boulevard Fleming, Besançon, FranceAlfred Penfornis, Department of Endocrinology-Metabolism and Diabetology-Nutrition, Jean Minjoz Hospital, EA 3920, University of Franche-Comté, Boulevard Fleming, Besançon 25000, France.E-mail: alfred.penfornis@univ-fcomte.frSearch for more papers by this author First published: 08 October 2010 https://doi.org/10.1111/j.1463-1326.2010.01311.xCitations: 9Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract Intravenous insulin therapy is the gold standard therapy for glycaemic control in hyperglycaemic critically ill adult patients. However, hypoglycaemia remains a major concern in critically ill patients, even in some populations who are not receiving infused insulin. Furthermore, the influence of factors such as glycaemic variability and nutritional support may conceal any benefit of strict glycaemic control on morbidity and mortality in these patients. The recently revised guidelines of the American Diabetic Association/American College of Clinical Endocrinologists no longer advocate very tight glycaemic control or normalization of glucose levels in all critically ill patients. In the light of various concerns over the optimal glucose level and means to achieve such control, the use of glucagon-like peptide-1 or its analogues administered intravenously may represent an interesting therapeutic option. Citing Literature Volume13, Issue2February 2011Pages 118-129 RelatedInformation